HC Wainwright reaffirmed their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $100.00 target price on the stock. Several other equities analysts have also weighed in on MLTX. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake […]

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. Several other equities research analysts also recently issued reports on the company. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on […]

Alumis (NASDAQ:ALMS – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $26.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 222.98% from the company’s current price. Other research analysts have […]

HC Wainwright restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $38.00 price target on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2029 earnings at ($0.69) EPS. Separately, Cantor Fitzgerald began coverage on shares […]

HC Wainwright reiterated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. Several other analysts have also recently weighed in on the company. JPMorgan Chase & Co. cut Neumora Therapeutics from an […]

HC Wainwright upgraded shares of RAPT Therapeutics (NASDAQ:RAPT – Free Report) from a neutral rating to a buy rating in a research report released on Thursday, MarketBeat Ratings reports. The brokerage currently has $10.00 price target on the stock. A number of other equities analysts have also recently weighed in on RAPT. Wells Fargo & […]